Stirnadel-Farrant HA, Xu X, Kwiatek J, Jain P, Meyers J, Candrilli S, Mines D, Datto CJ. Characteristics, treatment patterns, health care resource utilization and costs in patients with bullous pemphigoid: a retrospective analysis of US health insurance claims data. JAAD Int. 2023 Jun 9;13:117-25. doi: 10.1016/j.jdin.2023.04.014
Andronis L, Oppong RA, Manga N, Senanayake E, Gopal S, Charman S, Giri R, Luckraz H. Is the Venner-PneuX endotracheal tube system a cost-effective option for post cardiac surgery care? Ann Thorac Surg. 2018 Sep;106(3):757-63. doi: 10.1016/j.athoracsur.2018.03.058
Lairson DR, Parikh RC, Cormier JN, Wenyaw C, Du XL. Cost-utility analysis of treatments for advanced non-small cell lung cancer. Am J Pharm Benefits. 2015 Nov;7(6):271-9.
Karve SJ, Panish JM, Dirani RG, Candrilli SD. Health care utilization and costs among Medicaid-enrolled patients with schizophrenia experiencing multiple psychiatric relapses. Health Outcomes Res Med. 2012 Nov 1;3(4):e183-94.
Lopes M, Chulikavit M, Parikh R, Stern L, Liu Z, Rogerio J. Budget impact of everolimus in treating metastatic renal cell carcinoma. Am J Pharm Benefits. 2012;4(Special Issue):sp41-8.
Karve S, Misurski D, Miller J, Davis KL. Costs of sequelae associated with invasive meningococcal disease: findings from a US managed care population. Health Outcomes Res Med. 2011 Nov 1;2(4):e215-26.
McKenna SP, Whalley D, Doward LC. Which outcomes are important in schizophrenia? Int J Methods Psychiatr Res. 2000;9(1):S58-67.